Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01080820 · ClinicalTrials.gov registry record · Phase 1

A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers

A Phase 1 study of Healthy, sponsored by Jazz Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT01080820: Completed Phase 1 study of Healthy, sponsored by Jazz Pharmaceuticals.

NCT01080820 is a Phase 1 study of Healthy that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 36 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01080820, a Phase 1 study of Healthy, has completed, sponsored by Jazz Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the safety and tolerability of CMX157 and the amount of CMX157 that reaches the blood stream, the manner in which the body processes CMX157 and the time that it takes to eliminate CMX157 following one oral dose when given to healthy volunteers.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG CMX157
  • DRUG Viread

Study Locations (1)

Wisconsin

  • Covance - Madison

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2010-06
Est. Completion 2010-12
Phase Phase 1
Jazz Pharmaceuticals

128 total trials

What the finished NCT01080820 record still lists

NCT01080820 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01080820 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01080820 about?

NCT01080820 is a clinical study titled "A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers". The purpose of this study is to evaluate the safety and tolerability of CMX157 and the amount of CMX157 that reaches the blood stream, the manner in which the body processes CMX157 and the time that it takes to eliminate CMX157 following one oral dose when given to healthy volunteers.

What is the current status of trial NCT01080820?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2010-06. Estimated completion is 2010-12.

What conditions does trial NCT01080820 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01080820?

The interventions under investigation include: Placebo (DRUG), CMX157 (DRUG), Viread (DRUG).

Who is sponsoring clinical trial NCT01080820?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01080820 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01080820's enrollment target sits among peer trials

36 595th of 1090 higher than 469 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01080820, the US trial registry maintained by the National Library of Medicine. NCT01080820 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.